Investment Rating - The report maintains a "Buy" rating for Anta (2020 HK) with a target price of HKD 108.70, indicating a potential upside of 43.5% from the current price of HKD 75.75 [1][2][7]. Core Insights - Anta's revenue for 2025 is projected to grow by 13.3% year-on-year to RMB 80.22 billion, with net profit expected to increase by 13.9% to RMB 13.59 billion, slightly exceeding previous expectations [6][7]. - The company's operational efficiency remains resilient, with an operating profit margin improvement of 0.4 percentage points to 23.8% despite a slight decline in gross margin [6][7]. - Anta's long-term strategy of "single focus, multi-brand, globalization" continues to be effective, with expectations for revenue growth across its brands in 2026 [6][7]. Financial Summary - Revenue projections for Anta are as follows: - 2024: RMB 70.83 billion - 2025: RMB 80.22 billion - 2026E: RMB 86.10 billion - 2027E: RMB 91.89 billion - 2028E: RMB 97.33 billion - Year-on-year growth rates are expected to be 13.6% for 2024, 13.3% for 2025, and gradually declining to 5.9% by 2028 [5][10]. - Net profit forecasts are: - 2024: RMB 15.60 billion - 2025: RMB 13.59 billion - 2026E: RMB 13.93 billion - 2027E: RMB 14.90 billion - 2028E: RMB 16.05 billion [5][18]. Brand Performance - Anta brand revenue is expected to grow by 3.7% in 2025, while FILA is projected to see a 6.9% increase, focusing on high-end sports fashion [6][7]. - Other brands under Anta are anticipated to experience significant growth, with a 59.2% increase in revenue, showcasing the strength of the multi-brand strategy [6][7].

Investment Rating - The investment rating for the company is Neutral with a target price of HKD 37.00, indicating a potential upside of 13.2% from the current price of HKD 32.68 [1][3][13]. Core Insights - The company reported a total revenue of RMB 116.9 billion for Q4 2025, representing a year-on-year increase of 7%. The gross margin improved slightly by 0.2 percentage points to 20.8%, while the adjusted net profit decreased by 24% to RMB 6.35 billion [2][8]. - The company continues to face storage cost pressures and is focusing on advancements in AI and other innovative fields, as well as the international expansion of its automotive and AIoT businesses [2][7]. - The company forecasts total revenues of RMB 493.2 billion for 2026, with an adjusted EPS of RMB 1.53, maintaining previous estimates [7][9]. Financial Overview - Revenue projections for the company are as follows: - 2024: RMB 365.9 billion - 2025: RMB 457.3 billion - 2026E: RMB 493.2 billion - 2027E: RMB 551.0 billion - 2028E: RMB 599.9 billion [6][14]. - The adjusted net profit is expected to be: - 2024: RMB 23.7 billion - 2025: RMB 41.6 billion - 2026E: RMB 33.7 billion - 2027E: RMB 40.7 billion - 2028E: RMB 47.5 billion [6][14]. - The company’s market capitalization is approximately HKD 701.1 billion, with a 52-week high of HKD 60.15 and a low of HKD 31.58 [5][6]. Business Segments Performance - The automotive segment is projected to generate revenue of RMB 106.1 billion in 2025, with a year-on-year growth of 224%, and is expected to achieve positive operating profit [7]. - The AIoT segment is anticipated to generate RMB 123.2 billion in revenue, reflecting an 18% year-on-year increase, with an improved gross margin of 23.1% [7]. - The smartphone business is expected to see a revenue decline of 3%, with a gross margin decrease of 1.8 percentage points to 10.9% [7].

Investment Rating - The report maintains a "Neutral" rating for WuXi Biologics (2269 HK) with a target price raised to HKD 35.80, indicating a potential upside of 8.0% from the current price of HKD 33.14 [1][12]. Core Insights - The company is expected to see significant profit margin improvements in 2025, driven by new technologies and CMO (Contract Manufacturing Organization) services, with management guiding for high growth in 2026 [2][6]. - The revenue for 2025 is projected at RMB 21.8 billion, representing a year-on-year growth of 17%, with a notable increase in gross margin by 5.0 percentage points to 46.0% [6][13]. - The long-term growth strategy is evolving from scale expansion to structural upgrades and platform monetization, with a focus on complex new mechanism molecules as a core growth driver [6][7]. Financial Forecast Changes - Revenue projections for 2026 are set at RMB 24.98 billion, a decrease of 1.2% from previous estimates, while gross profit is expected to rise to RMB 11.66 billion, an increase of 4.8% [3][13]. - Adjusted net profit for 2026 is forecasted at RMB 6.64 billion, reflecting a 2.1% increase from prior estimates [3][13]. - The company anticipates a free cash flow growth of over 70% to RMB 2.3 billion in 2025, with a capital expenditure of approximately RMB 7.1 billion for 2026 [6][7]. Stock Performance - The stock has shown a year-to-date change of 5.41%, with a 52-week high of HKD 42.18 and a low of HKD 17.82 [5][12]. - The average daily trading volume is reported at 48.16 million shares [5]. Valuation Metrics - The current valuation corresponds to a price-to-earnings ratio of 21 times and a PEG ratio of 1.1 for 2026, indicating a reasonable valuation [6][11]. - The estimated enterprise value is RMB 132.32 billion, with a net cash position of RMB 9.27 billion [7][11]. Revenue and Profitability Projections - Revenue is expected to grow to RMB 29.06 billion by 2027 and RMB 33.74 billion by 2028, with corresponding EBIT margins improving over the forecast period [7][13]. - The net profit margin is projected to stabilize around 26.6% for 2026, reflecting a slight increase from previous years [3][14]. Market Position - WuXi Biologics is positioned as a leading player in the biopharmaceutical contract research and manufacturing sector, with a strong focus on innovative drug development and production capabilities [6][12].

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 51.00, indicating a potential upside of 59.4% from the current price of HKD 32.00 [1][6][11]. Core Insights - The company is expected to see a narrowing of losses in 2025, supported by a cash reserve of over HKD 2 billion post-IPO, which will bolster R&D and operations for the next 2-3 years. The commercialization performance of Fluorouracil after its inclusion in the medical insurance list is anticipated to drive significant sales growth in 2026 [2][6]. - The report highlights the potential of the differentiated pan-RAS pipeline, with upcoming data readouts for GFH375 in pancreatic and lung cancer expected to be promising. The next-generation RAS-targeted molecules are also anticipated to show early clinical success [2][6]. Financial Summary - The company is projected to generate revenue of RMB 1.30 billion in 2025, a 24% year-on-year increase, primarily from overseas collaboration income related to GFH375. R&D expenses are expected to decrease by 15% due to reduced licensing costs associated with Fluorouracil [6][12]. - The adjusted loss for 2025 is forecasted to narrow by 9% to RMB 227 million, with operating cash outflow decreasing by 34% to RMB 136 million. The year-end cash and bank balance is expected to exceed RMB 2 billion, providing a solid foundation for future R&D and operations [6][12]. - Revenue projections for 2026E are set at USD 85 million, with gross profit expected to be USD 33 million, maintaining a gross margin of 39.3% [6][12]. Pipeline and Catalysts - The report emphasizes several upcoming catalysts, including the completion of patient enrollment for GFH375 in Phase III trials for pancreatic cancer and the initiation of registration studies for non-small cell lung cancer (NSCLC). Additionally, the confirmation of the recommended Phase II dose (RP2D) for GFH276 and the entry of more preclinical products into IND applications are highlighted as key developments [6][12].

Investment Rating - The investment rating for H&H International Holdings is "Buy" (maintained) [1] Core Views - H&H International Holdings reported its 2025 annual performance, achieving revenue of 14.35 billion RMB, a year-on-year increase of 10% [7] - The company demonstrated resilience in its infant probiotics and nutritional products segment, with revenue stabilizing at a 2% year-on-year growth, contrasting with a decline of 32% in 2024 [7] - The management's strategic focus on long-term growth and compliance has been highlighted, particularly in the Australian and New Zealand (ANC) market, where revenue growth is expected despite a temporary contraction due to regulatory adjustments [7] Financial Summary - Total revenue projections for H&H International Holdings are as follows: 13.05 billion RMB for 2024, 14.35 billion RMB for 2025, 16.04 billion RMB for 2026, 17.97 billion RMB for 2027, and 20.07 billion RMB for 2028, with respective year-on-year growth rates of -6.28%, 9.97%, 11.76%, 12.02%, and 11.71% [1][8] - The net profit attributable to the parent company is forecasted to be -53.72 million RMB for 2024, 196.14 million RMB for 2025, 634.78 million RMB for 2026, 873.64 million RMB for 2027, and 1.12 billion RMB for 2028, reflecting significant growth rates of -109.23%, 465.11%, 223.64%, 37.63%, and 27.89% respectively [1][8] - The latest diluted EPS is projected to be -0.08 RMB for 2024, 0.30 RMB for 2025, 0.98 RMB for 2026, 1.35 RMB for 2027, and 1.73 RMB for 2028 [1][8] - The current P/E ratios are 131.66 for 2024, 36.06 for 2025, 11.14 for 2026, 8.10 for 2027, and 6.33 for 2028 [1][8]

Investment Rating - The report maintains a "Buy" rating for Xiaomi Group [1] Core Viewpoints - The report highlights the need to evaluate performance following earnings announcements, indicating a wait for a fundamental turning point and the emergence of AI strategic visions [6] - Xiaomi's revenue for Q4 2025 reached 116.9 billion RMB, a year-on-year increase of 7%, marking five consecutive quarters of revenue exceeding 100 billion RMB [8] - The report anticipates a decline in smartphone shipments to 150 million units in 2026, a 9% year-on-year decrease, while maintaining an average selling price (ASP) increase of 5% [8] - The Internet of Things (IoT) segment is expected to see revenue growth of 10% in 2026, despite a slowdown due to national subsidies and increased competition [8] - The report projects a total revenue of 504.8 billion RMB for 2026, with a net profit of 33.4 billion RMB, reflecting a 15% decrease from previous estimates [8] - The AI strategy is expected to see an investment of 60 billion RMB from 2026 to 2028, with 16 billion RMB allocated for 2026 [8] Financial Data and Profit Forecast - Revenue projections for Xiaomi Group are as follows: - 2024: 365.9 billion RMB - 2025: 457.3 billion RMB - 2026E: 504.8 billion RMB - 2027E: 593.0 billion RMB - 2028E: 698.0 billion RMB [7] - Adjusted net profit forecasts are: - 2024: 27.3 billion RMB - 2025: 39.2 billion RMB - 2026E: 33.4 billion RMB - 2027E: 41.4 billion RMB - 2028E: 51.4 billion RMB [7] - The report indicates a projected PE ratio of 31 for the main business in 2026, with a target valuation of 986.7 billion RMB, representing a 33% upside potential [8][15]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of HKD 19 [2][8]. Core Insights - The company achieved a revenue of HKD 6.613 billion in 2025, representing a year-on-year growth of 1.12%, and a net profit attributable to shareholders of HKD 854 million, up 15.49% year-on-year [2][4]. - The second half of 2025 saw revenue of HKD 3.685 billion, a 2.01% increase year-on-year, and a net profit of HKD 544 million, reflecting a significant growth of 26.29% year-on-year [2][4]. - The company is expected to continue its stable revenue growth in 2026, driven by overseas expansion and improvements in the B-end business, with a projected revenue growth rate of 6.0% [4][8]. Financial Performance Summary - Total revenue for 2025 is projected at HKD 6,613 million, with a year-on-year growth rate of 1.1% [4]. - The net profit attributable to shareholders is expected to reach HKD 854 million in 2025, with a growth rate of 15.5% [4]. - Earnings per share (EPS) for 2026 is estimated at HKD 0.93, with a price-to-earnings (P/E) ratio of 15 times [4][8]. - The company’s gross margin for 2025 is reported at 32.8%, with a net profit margin of 12.9%, both showing slight improvements year-on-year [8][9]. Revenue Breakdown - In 2025, revenue from the company's affiliated and third-party businesses was HKD 18.31 billion and HKD 47.81 billion, respectively, with year-on-year changes of -7.2% and +4.7% [8]. - The second half of 2025 showed improvements in the affiliated business, with revenue changes of -1.8% and +3.4% for affiliated and third-party businesses, respectively [8]. - Product-wise, revenue from hot pot base, Chinese seasoning, and instant food was HKD 40.38 billion, HKD 9.16 billion, and HKD 15.64 billion, with respective year-on-year changes of -1.2%, +16.4%, and -2.5% [8]. Future Outlook - The company is expected to maintain a growth trajectory in 2026, with clear growth drivers including overseas market expansion and enhancements in the B-end business [8]. - The report anticipates that the company will continue to optimize its channel strategies and product pricing, contributing to improved profit margins [8].

Investment Rating - The report maintains an "Outperform" rating for Yihai International [2][12]. Core Insights - The company reported a full-year revenue of RMB 6.61 billion for 2025, reflecting a year-over-year increase of 1.1%, and a net profit attributable to shareholders of RMB 850 million, up 15.5% year-over-year [3][9]. - In the second half of 2025, revenue reached RMB 3.69 billion, a 2.0% increase year-over-year, with net profit attributable to shareholders at RMB 550 million, up 22.9% year-over-year, indicating significant quarter-over-quarter improvement [3][9]. - The company’s strategy to enhance the premium positioning of third-party products has shown significant results, with hot pot seasonings accounting for 61.1% of total revenue in 2025 [10][12]. Financial Performance Summary - Revenue projections for 2026-2028 are estimated at RMB 7.00 billion, RMB 7.62 billion, and RMB 8.21 billion, respectively, with net profits of RMB 1.01 billion, RMB 1.12 billion, and RMB 1.22 billion [13]. - The diluted EPS for 2026-2028 is projected to be RMB 0.97, RMB 1.08, and RMB 1.18, respectively [13]. - The gross margin in the second half of 2025 increased by 2.9 percentage points year-over-year, with net profit margin also expanding by 2.8 percentage points [11][12]. Business Segment Analysis - Hot pot dipping sauces generated RMB 510 million in revenue, up 16.4% year-over-year, while compound seasonings also saw a 16.4% increase, driven by strong growth in niche categories [10]. - The third-party business generated revenue of RMB 4.78 billion, up 4.7% year-over-year, with overseas sales increasing by 45.4% and B2B revenue rising by 73.3% [10][11]. - Related-party revenue contracted by 11.0% year-over-year due to a focus on high-margin third-party categories [10].

Investment Rating - The report assigns a "Neutral" rating to WuXi Biologics (2269 HK) with a target price raised to HKD 35.80, indicating a potential upside of 8.0% from the current price of HKD 33.14 [1][12]. Core Insights - The company continues to show strong growth, with a significant improvement in gross margin and management guidance indicating high growth for 2026. The order structure is being upgraded due to new technology and CMO-driven strategies, providing strong long-term growth visibility [2][6]. - The revenue for 2025 is projected at RMB 21.8 billion, representing a year-on-year growth of 17%. The gross margin is expected to increase by 5.0 percentage points to 46.0% [6][13]. - The long-term growth logic is evolving from scale expansion to structural upgrades and platform monetization, with complex new mechanism molecules becoming a core growth driver [6][7]. Financial Forecast Changes - Revenue projections for 2026 are set at RMB 24.98 billion, a decrease of 1.2% from previous estimates. However, gross profit is expected to rise to RMB 11.66 billion, reflecting a 4.8% increase [3][13]. - The adjusted net profit for 2026 is forecasted at RMB 6.64 billion, with a net profit margin of 26.6%, an increase of 0.9 percentage points from the previous forecast [3][13]. Stock Performance - The stock has shown a neutral performance over the past year, with a year-to-date change of 5.41% [4][5]. - The stock's 52-week high is HKD 42.18, and the low is HKD 17.82, indicating significant volatility [5]. Valuation Metrics - The current valuation corresponds to a price-to-earnings ratio of 21 times and a PEG ratio of 1.1 for 2026, which is considered reasonable [6][11].

Investment Rating - The report maintains a "Buy" rating for the company [4] Core Insights - The company achieved total revenue of 16.462 billion yuan in 2025, representing a year-on-year growth of 11.54%, while the net profit attributable to the parent company was 420 million yuan, a decrease of 13.10% year-on-year [4][2] - In the second half of 2025, revenue reached 8.585 billion yuan, with a year-on-year increase of 12.47%, and the net profit attributable to the parent company was 113 million yuan [4] - The company has established itself as the largest automotive service platform globally, with a total of 8,008 stores by the end of 2025, marking a 16.5% increase year-on-year [1][2] User Growth and Engagement - By the end of 2025, the registered user base reached 162 million, a year-on-year increase of 16.9%, with 28.4 million active transaction users, up 17.7% year-on-year [2] - User retention has improved significantly, with the annual repurchase rate increasing by 2.7 percentage points to 65.0% [2] Supply Chain and Technology - The company has enhanced its supply chain efficiency with 31 regional warehouses and 738 front warehouses, utilizing smart inventory algorithms [2] - The implementation of AI technology has improved the conversion rate of intelligent product recommendations by 10% year-on-year [2] Financial Forecast - Projected revenues for 2026-2028 are 18.151 billion yuan, 20.013 billion yuan, and 22.022 billion yuan, respectively, with net profits expected to be 470 million yuan, 610 million yuan, and 770 million yuan [2][3]